查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929620

全球白血球塑膠血袋市場（按血液成分、產品類型、白血球去除類型、材料和最終用戶分類）預測（2026-2032年）

Leukocyte Plastic Blood Bag Market by Blood Component, Product Type, Leukoreduction Type, Material, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年白血球塑膠血袋市場價值為 12 億美元，預計到 2026 年將成長至 12.9 億美元，年複合成長率為 7.17%，到 2032 年將達到 19.5 億美元。

主要市場統計數據
基準年 2025 12億美元
預計年份：2026年 12.9億美元
預測年份：2032年 19.5億美元
複合年成長率 (%) 7.17%

醫療保健相關人員的權威白血球去除塑膠血袋說明，涵蓋臨床應用、材料考量和操作決策要點。

用於白血球去除的塑膠血袋在現代輸血醫學及相關生物醫學工作流程中發揮著至關重要的作用，它們是血液成分採集、儲存和白血球去除過程的物理介面。這些專用血袋的設計旨在滿足臨床、監管和操作需求，同時最大限度地減少細胞損傷並保持成分完整性。在醫院、血庫、診斷實驗室和研究實驗室中，血袋的配置、材料和白血球去除方法的選擇會影響下游製程的兼容性、儲存穩定性以及輸血效果。

新興的過濾方法、材料創新和整合處理模型如何重塑臨床和檢查室環境中的產品需求和採購重點

由於技術、法規和臨床實踐的變革，用於白血球去除的塑膠血袋市場格局正在轉變，這些變革共同重新定義了產品要求和採購標準。白血球去除技術和過濾材料的進步推動了對能夠同時滿足儲存前後白血球去除流程的血袋套裝的需求，使臨床團隊能夠根據預期的臨床應用客製化流程，同時降低免疫風險。同時，人們日益關注材料的生物相容性和永續性，這促使人們對聚乙烯和聚丙烯等替代材料產生興趣，這些材料具有獨特的滅菌和保存性能，可取代傳統的聚氯乙烯。

評估2025年關稅調整對醫療耗材籌資策略的多面向供應鏈、採購和監管影響

2025年關稅的累積影響已對醫療拋棄式產品供應鏈造成了顯著的摩擦，尤其對白血球分離術用塑膠血袋的生產商和採購商影響尤為顯著。關稅調整影響了聚合物樹脂原料、過濾組件和某些輔助材料的到岸成本，迫使生產商重新評估其籌資策略和生產地點，以維持成本競爭力和合約利潤率。為此，一些供應商已採取措施來緩解關稅波動帶來的物流和財務不確定性，例如實現供應來源多元化、轉移生產流程或增加關鍵材料的庫存。

詳細的細分分析重點在於血液成分類型、血袋規格、白血球去除時間、最終用戶畫像和材料選擇等因素，這些因素共同驅動產品策略和採購標準。

了解血液成分細分的細微差別對於協調用於白血球去除的塑膠血袋的產品開發、採購和臨床應用策略至關重要。從血液成分的角度來看，產品設計必須能夠滿足血漿、血小板和紅血球的工作流程。血漿進一步細分為冷沉澱血漿和新鮮冷凍血漿，血小板又細分為單採血小板和白血球層血小板，紅血球則根據成人和兒童用途進行分類。這些差異會影響血袋的結構、管路配置和過濾方式，從而導致最終用戶對產品規格的差異。

區域趨勢和監管差異（美洲、歐洲、中東和非洲、亞太地區）對產品推出、生產重點和策略聯盟的影響

區域趨勢是白血球去除塑膠血袋生產商和買家策略的關鍵，美洲、歐洲、中東和非洲以及亞太地區之間存在顯著差異。在美洲，廣泛的醫院網路和完善的血庫基礎設施影響需求模式，優先考慮與自動化處理設備的兼容性和符合監管要求。這推動了對多袋系統和檢驗的白血球去除解決方案的需求，同時也促進了供應商與中央血液服務機構之間的合作，以簡化分銷流程。

供應商如何透過材料科學、檢驗的白血球減少解決方案、區域企業發展和服務主導支援來脫穎而出，從而確保長期的臨床和採購夥伴關係

白血球去除塑膠血袋市場的競爭融合了產品創新、製造地最佳化和服務導向的定位。主要企業強調檢驗的品質系統、豐富的血袋套裝配置以及材料方面的專業知識，以滿足血庫、醫院、診斷實驗室和檢驗機構的多樣化需求。策略差異化通常取決於能否在儲存前後階段整合白血球去除解決方案，同時確保與自動化平台和封閉式系統處理通訊協定的兼容性。

為製造商和醫療保健領導者提供切實可行的策略步驟，以增強供應鏈韌性、加速臨床應用，並協調產品設計的永續性和檢驗要求。

產業領導者應優先採取一系列策略行動，以增強韌性、提高臨床適用性並加速推廣先進的白血球去除塑膠血袋解決方案。首先，投資關鍵原料的雙重採購，並考慮區域生產能力，以降低貿易政策干擾風險並縮短前置作業時間。這將提高供應連續性，並在與供應商談判時獲得優勢，同時確保符合無菌和檢驗要求。其次，透過提供模組化血袋組件配置和用於儲存前後白血球去除的過濾選項，使產品系列與臨床工作流程相匹配，並確保與常用自動化平台相容。

我們採用嚴謹的混合研究方法，結合關鍵相關人員對話、技術檢驗和監管審查，為產品和籌資策略。

本研究系統地結合了訪談、實驗室評估、監管文件審查和文獻分析等證據，對白血球去除塑膠血袋進行了權威性闡述。主要資訊來源包括對血庫主任、醫院採購負責人、實驗室經理和研發專業人員的結構化訪談，以了解營運重點、採購限制和臨床工作流程要求。此外，還對血袋材料、滅菌製程和白血球去除過濾器進行了技術評估，以了解性能權衡和檢驗要求。

我們整合了臨床需求、材料創新、供應鏈韌性和籌資策略等因素，最終得出定義該領域成功的結論。

總之，白血球去除塑膠血袋仍是輸血醫學和檢查室工作流程的基礎要素，其產品選擇和採購決策受到臨床需求、材料科學、監管要求和供應鏈動態等許多因素的複雜影響。向一體化加工、先進的白血球去除技術和替代聚合物的持續轉變，凸顯了供應商在推動創新的同時，確保與現有臨床生態系統相容性的必要性。同時，採購負責人必須權衡成本因素與供應彈性、檢驗負擔和臨床性能等要求。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 白血球塑膠血袋市場（依血液成分分類）

  • 電漿
    • 冷沉澱物
    • 新鮮冷凍血漿
  • 血小板
    • 血液分離術
    • 巴菲外套
  • 紅血球
    • 成人版
    • 兒童

9. 白血球塑膠血袋市場（依產品類型分類）

  • 雙袋套裝
  • 四件套
  • 單袋套裝
  • 三件套

第10章 白血球去除類型下的塑膠血袋市場

  • 儲存後
  • 儲存前

第11章 白血球塑膠血袋市場（依材料分類）

  • 非氯乙烯
    • 聚乙烯
    • 聚丙烯
  • 聚氯乙烯

第12章 白血球塑膠血袋市場（依終端用戶分類）

  • 血庫
  • 檢查室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所

第13章 白血球塑膠血袋市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 白血球塑膠血袋市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國白血球塑膠血袋市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國白血球塑膠血袋市場

第17章：中國白血球塑膠血袋市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Beijing Bodesant Medical Technology Co., Ltd.
  • Celgene Biomedical Co., Ltd.
  • Danaher Corporation
  • Fenwal, Inc.
  • Fresenius SE & Co. KGaA
  • Grifols SA
  • Haemonetics Corporation
  • HLL Lifecare Limited
  • JMS Co., Ltd.
  • JOKOH Co., Ltd.
  • MacoPharma SA
  • Nigale Biomedical Co., Ltd.
  • Nipro Corporation
  • Poly Medicure Limited
  • Shandong Zhongbaokang Medical Technology Co., Ltd.
  • Shanghai Wells Healthcare Co., Ltd.
  • Span Healthcare Private Limited
  • Sun Meditech Co., Ltd.
  • Terumo Corporation
  • Wego Group
Product Code: MRR-0A380695184F

The Leukocyte Plastic Blood Bag Market was valued at USD 1.20 billion in 2025 and is projected to grow to USD 1.29 billion in 2026, with a CAGR of 7.17%, reaching USD 1.95 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.20 billion
Estimated Year [2026] USD 1.29 billion
Forecast Year [2032] USD 1.95 billion
CAGR (%) 7.17%

An authoritative introduction to leukocyte plastic blood bags that frames clinical roles, material considerations, and operational decision points for healthcare stakeholders

Leukocyte plastic blood bags occupy a critical role in modern transfusion medicine and related biomedical workflows, serving as the physical interface for blood component collection, storage, and leukoreduction processes. These specialized bags are engineered to meet clinical, regulatory, and operational demands while minimizing cell damage and preserving component integrity. In hospitals, blood banks, diagnostic laboratories, and research institutes, the selection of blood bag configurations, materials, and leukoreduction approaches influences downstream compatibility, storage stability, and transfusion outcomes.

Today's stakeholders face a complex set of technical and administrative choices when specifying blood bag systems. Decisions span component types such as plasma, platelets, and red blood cells, with further differentiation by component subtypes that reflect clinical usage patterns and storage requirements. Product type selection ranges across single to multi-bag set configurations that integrate transfer tubing, filters, and satellite bags for fractionation and leukoreduction. Material science considerations, including polyvinyl chloride and non-PVC alternatives, affect biocompatibility, plasticizer migration, and sterilization strategies.

Across clinical and laboratory settings, trends toward improved safety, streamlined processing, and regulatory compliance are reshaping procurement priorities. With that in mind, this executive-level document synthesizes recent shifts, tariff impacts, segmentation insights, regional dynamics, competitive behavior, and practical recommendations to inform leadership decisions and operational planning for organizations engaged with leukocyte plastic blood bag supply and utilization

How emerging filtration methods, material innovations, and integrated processing models are reshaping product requirements and procurement priorities across clinical and laboratory settings

The landscape for leukocyte plastic blood bags is undergoing transformative shifts driven by technological, regulatory, and clinical practice changes that together are redefining product requirements and procurement criteria. Advances in leukoreduction techniques and filtration materials are increasing demand for bag sets that can support both pre-storage and post-storage leukoreduction workflows, thereby enabling clinical teams to tailor processing to anticipated clinical use while mitigating immunologic risks. At the same time, growing attention to material biocompatibility and sustainability is stimulating interest in alternatives to conventional polyvinyl chloride, including polyethylenes and polypropylenes that offer distinct sterilization and storage characteristics.

Simultaneously, hospitals and blood centers are adopting more integrated processing models that rely on multi-bag set configurations such as double, triple, and quadruple bag systems to facilitate component separation and closed-system operations. This integration supports efficiency gains and reduces contamination risk, which in turn affects purchasing specifications and supplier evaluation criteria. Regulatory emphasis on traceability, sterilization validation, and compatibility with automated processing equipment is also elevating product development priorities, prompting manufacturers to invest in innovations that ensure compliance across diverse jurisdictions.

Finally, clinical demand patterns for plasma, platelets, and red blood cells are evolving alongside demographic and therapeutic trends, necessitating flexible product portfolios that accommodate adult and pediatric use, apheresis and buffy coat platelet collection methods, and plasma formats such as cryoprecipitate and fresh frozen plasma. These shifts highlight the importance of strategic alignment between clinical practice and supply chain decisions, as organizations aim to secure products that safeguard patient outcomes while optimizing operational performance

Assessing the multifaceted supply chain, sourcing, and regulatory consequences of United States tariff adjustments implemented in 2025 on medical disposable procurement strategies

The cumulative impact of tariff actions implemented in the United States in 2025 has introduced measurable friction into supply chains for medical disposables, with specific ramifications for manufacturers and buyers of leukocyte plastic blood bags. Tariff adjustments have affected the landed cost of raw polymer resins, filtration components, and certain ancillary materials, prompting manufacturers to reassess sourcing strategies and production footprints in order to preserve cost competitiveness and contractual margins. In response, several suppliers have diversified supplier bases, relocated production stages, or increased inventories of critical inputs to mitigate the logistical and financial uncertainties stemming from tariff volatility.

Alongside supplier-side adjustments, healthcare providers and group purchasing organizations have revisited procurement contracts, placing greater emphasis on total cost of ownership, lead-time certainty, and alternative sourcing options. These shifts have heightened the appeal of domestically produced or regionally sourced bag systems where feasible, as proximity to manufacturing can reduce exposure to cross-border tariff fluctuations and shipping delays. Additionally, some organizations have negotiated longer-term agreements with conditional price adjustment clauses to balance fiscal responsibility with supply continuity.

Regulatory and compliance considerations have further complicated responses to tariffs, since substituting materials or changing suppliers can trigger requalification activities, additional sterility validations, and updated device master records. Consequently, procurement and clinical engineering teams are collaborating more closely with suppliers to ensure that any supply chain reconfiguration preserves product performance characteristics and regulatory compliance. Overall, the tariff environment in 2025 accelerated strategic prioritization of supply resilience, supplier diversification, and contract design to reduce exposure to future trade policy shifts

Deep segmentation analysis revealing how component types, bag configurations, leukoreduction timing, end-user profiles, and material choices determine product strategy and procurement criteria

A nuanced understanding of segmentation is essential for aligning product development, procurement, and clinical adoption strategies for leukocyte plastic blood bags. When viewed through the prism of blood component, product designs must serve plasma, platelet, and red blood cell workflows, with plasma further differentiated by cryoprecipitate and fresh frozen plasma formats, platelets subdivided into apheresis and buffy coat pathways, and red blood cells classified by adult and pediatric applications. These distinctions influence bag architecture, tubing configuration, and filtration options, driving specification variance across end users.

Product type segmentation-from single bag sets to double, triple, and quadruple bag configurations-determines how blood components are fractionated and how closed-system processing is orchestrated in blood banks and hospital settings. Multi-bag systems support complex separation and transfer steps without compromising sterility, whereas single bag solutions can favor simplicity and lower per-unit cost for limited processing requirements. The choice between pre-storage and post-storage leukoreduction approaches affects when filtration occurs in the processing timeline and dictates filter integration, handling protocols, and validation workflows.

End-user segmentation-spanning blood banks, diagnostic laboratories, hospitals, and research institutes-drives procurement criteria tied to throughput, equipment compatibility, regulatory oversight, and clinical complexity, with hospitals further delineated between private and public facilities that may operate under differing procurement rules. Material segmentation contrasts polyvinyl chloride with non-PVC alternatives such as polyethylene and polypropylene, each offering different chemical compatibility profiles, sterilization tolerances, and environmental footprints. Together, these segmentation vectors form an interlocking framework that informs specification development, supplier selection, and product roadmaps for stakeholders across the value chain

Regional dynamics and regulatory diversity across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence product adoption, manufacturing priorities, and strategic partnerships

Regional dynamics are central to strategy for manufacturers and buyers of leukocyte plastic blood bags, and they vary significantly across the Americas, Europe Middle East & Africa, and Asia-Pacific territories. In the Americas, demand patterns are influenced by extensive hospital networks and established blood banking infrastructures that prioritize product compatibility with automated processing equipment and regulatory conformity. This fosters demand for multi-bag systems and validated leukoreduction solutions, while also encouraging partnerships between suppliers and centralized blood services to streamline distribution.

Europe Middle East & Africa presents a heterogeneous regulatory environment with diverse procurement practices across national health systems and private providers. In this region, attention to material compliance, traceability, and cross-border certification is pronounced, prompting suppliers to emphasize conformity with regional and national standards. Middle Eastern and African markets may exhibit accelerating investment in blood services and laboratory modernization, creating opportunities for tailored product offerings and localized support models.

Asia-Pacific encompasses a mix of mature healthcare markets and rapidly expanding systems where scalability and cost-effectiveness are core considerations. Manufacturers seeking growth here often tailor product portfolios to accommodate varied clinical practices, such as apheresis prevalence in specific countries, while also addressing material preferences and sterilization infrastructure. Across all regions, regulatory harmonization efforts, local manufacturing incentives, and healthcare modernization initiatives shape the competitive landscape and influence decisions about where to prioritize investment, production, and strategic partnerships

How suppliers differentiate through material science, validated leukoreduction solutions, regional footprints, and service-driven support to secure long-term clinical and procurement partnerships

Competitive dynamics among companies operating in the leukocyte plastic blood bag space reflect a blend of product innovation, manufacturing footprint optimization, and service-oriented positioning. Leading suppliers emphasize validated quality systems, breadth of bag set configurations, and material expertise to meet the diverse needs of blood banks, hospitals, diagnostic laboratories, and research institutes. Strategic differentiation often hinges on the ability to integrate filtration solutions for both pre-storage and post-storage leukoreduction while ensuring compatibility with automation platforms and closed-system processing protocols.

Manufacturers investing in alternative polymers and improved filtration media seek to address clinical concerns about plasticizer migration and sterilization resilience, thereby offering procurement teams options aligned with institutional priorities around safety and environmental stewardship. At the same time, firms with regional manufacturing or distribution capabilities can offer resilience against tariff-induced cost volatility and supply disruptions, which is increasingly valued by large health systems and centralized blood services.

Service propositions, including validation support, training, and post-sales technical assistance, are central to winning long-term contracts. Companies that can couple robust product portfolios with hands-on implementation support and rapid regulatory documentation are often favored in tender processes. Collaboration with clinical researchers and participation in comparative performance studies can further strengthen market positioning, as such evidence helps clinicians and procurement leaders assess real-world outcomes linked to bag design and leukoreduction strategy

Actionable strategic measures for manufacturers and healthcare leaders to build supply resilience, accelerate clinical adoption, and align product design with sustainability and validation needs

Industry leaders should prioritize a set of strategic actions to strengthen resilience, enhance clinical compatibility, and accelerate adoption of advanced leukocyte plastic blood bag solutions. First, invest in dual-source procurement for critical raw materials and consider regional production capacity to mitigate exposure to trade policy disruptions and to shorten lead times. Doing so improves supply continuity and provides negotiating leverage with suppliers while maintaining compliance with sterility and validation requirements. Secondly, align product portfolios with clinical workflows by offering modular bag set configurations and filtration options that accommodate pre-storage and post-storage leukoreduction while ensuring compatibility with common automation platforms.

Next, accelerate material innovation efforts by evaluating non-PVC alternatives and advanced polymer blends that meet sterilization and storage demands without compromising biocompatibility. Pair material development with robust toxicological and migration testing to satisfy regulatory scrutiny and institutional procurement policies. Additionally, embed lifecycle and environmental considerations into product design and documentation to meet growing institutional mandates for sustainability and waste reduction.

Finally, deepen collaborations with clinical stakeholders and blood services to generate real-world evidence of performance, and enhance post-sales services including validation support, training, and rapid response maintenance. These efforts strengthen customer trust and facilitate smoother adoption pathways. Implement flexible contracting models that balance price stability with supply assurance, and use scenario planning to prepare for future trade or regulatory shifts. Collectively, these actions help organizations secure a competitive advantage while supporting patient safety and operational efficiency

A rigorous mixed-methods research approach combining primary stakeholder engagement, technical validation, and regulatory review to produce actionable insights for product and procurement strategies

This research synthesizes evidence from a structured combination of primary interviews, laboratory evaluations, regulatory documentation reviews, and secondary literature analysis to construct an authoritative perspective on leukocyte plastic blood bags. Primary inputs included structured interviews with blood bank directors, hospital procurement leads, laboratory managers, and R&D professionals to capture operational priorities, procurement constraints, and clinical workflow requirements. Complementing these insights, technical assessments of bag materials, sterilization processes, and leukoreduction filters were analyzed to understand performance trade-offs and validation requirements.

Regulatory document reviews provided context on compliance expectations, traceability mandates, and device classification pathways across major jurisdictions, while procurement contract clauses and tender specifications were examined to delineate commercial terms that influence supplier selection. Secondary literature and publicly available technical standards were used to contextualize material science trends and to validate claims related to sterilization, biocompatibility, and handling protocols. Cross-validation between qualitative interviews and technical data ensured that findings reflect both practitioner experience and empirical performance considerations.

Segmentation analysis was constructed by mapping product attributes to end-user requirements, incorporating distinctions by blood component, bag configuration, leukoreduction timing, end-user type, and material. Regional dynamics were informed by policy reviews, healthcare infrastructure assessments, and stakeholder interviews in the Americas, Europe Middle East & Africa, and Asia-Pacific. Together, these methods produced a cohesive, actionable synthesis designed to support strategic decision-making and operational planning

An integrated conclusion summarizing the interplay of clinical needs, material innovations, supply resilience, and procurement strategies that will define success in the sector

In conclusion, leukocyte plastic blood bags remain a foundational component of transfusion medicine and laboratory workflows, with product selection and procurement decisions influenced by a complex interplay of clinical requirements, material science, regulatory mandates, and supply chain dynamics. The ongoing shift toward integrated processing, advanced leukoreduction, and alternative polymer adoption underscores the need for suppliers to innovate while ensuring compatibility with existing clinical ecosystems. At the same time, procurement professionals must balance cost considerations with supply resilience, validation burdens, and clinical performance imperatives.

Tariff-driven disruptions in 2025 highlighted the strategic value of regional manufacturing footprints and diversified sourcing strategies, reinforcing the importance of contractual flexibility and stronger supplier collaboration. Segmentation insights demonstrate that one-size-fits-all approaches are insufficient; instead, product portfolios must address the specific needs of plasma, platelet, and red blood cell workflows, different bag set configurations, leukoreduction timing preferences, varied end-user profiles, and material choices.

For organizations seeking to optimize outcomes, a combination of targeted product innovation, investment in supply chain resilience, and deeper clinical partnerships will be essential. Executives should prioritize evidence generation through clinical collaborations and pilot implementations while proactively managing supplier relationships and regulatory requirements to ensure continuity of care and operational excellence

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Leukocyte Plastic Blood Bag Market, by Blood Component

  • 8.1. Plasma
    • 8.1.1. Cryoprecipitate
    • 8.1.2. Fresh Frozen Plasma
  • 8.2. Platelet
    • 8.2.1. Apheresis
    • 8.2.2. Buffy Coat
  • 8.3. Red Blood Cell
    • 8.3.1. Adult
    • 8.3.2. Pediatric

9. Leukocyte Plastic Blood Bag Market, by Product Type

  • 9.1. Double Bag Set
  • 9.2. Quadruple Bag Set
  • 9.3. Single Bag Set
  • 9.4. Triple Bag Set

10. Leukocyte Plastic Blood Bag Market, by Leukoreduction Type

  • 10.1. Post Storage
  • 10.2. Pre Storage

11. Leukocyte Plastic Blood Bag Market, by Material

  • 11.1. Non Polyvinyl Chloride
    • 11.1.1. Polyethylene
    • 11.1.2. Polypropylene
  • 11.2. Polyvinyl Chloride

12. Leukocyte Plastic Blood Bag Market, by End User

  • 12.1. Blood Bank
  • 12.2. Diagnostic Laboratory
  • 12.3. Hospital
    • 12.3.1. Private Hospital
    • 12.3.2. Public Hospital
  • 12.4. Research Institute

13. Leukocyte Plastic Blood Bag Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Leukocyte Plastic Blood Bag Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Leukocyte Plastic Blood Bag Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Leukocyte Plastic Blood Bag Market

17. China Leukocyte Plastic Blood Bag Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun Melsungen AG
  • 18.6. Baxter International Inc.
  • 18.7. Beijing Bodesant Medical Technology Co., Ltd.
  • 18.8. Celgene Biomedical Co., Ltd.
  • 18.9. Danaher Corporation
  • 18.10. Fenwal, Inc.
  • 18.11. Fresenius SE & Co. KGaA
  • 18.12. Grifols S.A.
  • 18.13. Haemonetics Corporation
  • 18.14. HLL Lifecare Limited
  • 18.15. JMS Co., Ltd.
  • 18.16. JOKOH Co., Ltd.
  • 18.17. MacoPharma SA
  • 18.18. Nigale Biomedical Co., Ltd.
  • 18.19. Nipro Corporation
  • 18.20. Poly Medicure Limited
  • 18.21. Shandong Zhongbaokang Medical Technology Co., Ltd.
  • 18.22. Shanghai Wells Healthcare Co., Ltd.
  • 18.23. Span Healthcare Private Limited
  • 18.24. Sun Meditech Co., Ltd.
  • 18.25. Terumo Corporation
  • 18.26. Wego Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY CRYOPRECIPITATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY CRYOPRECIPITATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY CRYOPRECIPITATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY FRESH FROZEN PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY FRESH FROZEN PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY FRESH FROZEN PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY APHERESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY APHERESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY APHERESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BUFFY COAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BUFFY COAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BUFFY COAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DOUBLE BAG SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DOUBLE BAG SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DOUBLE BAG SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY QUADRUPLE BAG SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY QUADRUPLE BAG SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY QUADRUPLE BAG SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY SINGLE BAG SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY SINGLE BAG SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY SINGLE BAG SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY TRIPLE BAG SET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY TRIPLE BAG SET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY TRIPLE BAG SET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POST STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POST STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POST STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRE STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRE STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRE STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD BANK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD BANK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD BANK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 190. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 191. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 192. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 223. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 224. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 225. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 229. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 234. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 235. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 236. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 237. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 240. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY BLOOD COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLASMA, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PLATELET, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY RED BLOOD CELL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY LEUKOREDUCTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA LEUKOCYTE PLASTIC BLOOD BAG MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)